.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,273,341

« Back to Dashboard

Claims for Patent: 8,273,341

Title:Antiviral compounds
Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Inventor(s): Guo; Hongyan (Foster City, CA), Kato; Darryl (Foster City, CA), Kirschberg; Thorsten A. (Foster City, CA), Liu; Hongtao (Foster City, CA), Link; John O. (Foster City, CA), Mitchell; Michael L. (Foster City, CA), Parrish; Jay P. (Foster City, CA), Graupe; Michael (Foster City, CA), Sun; Jianyu (Foster City, CA), Taylor; James (Foster City, CA), Bacon; Elizabeth M. (Foster City, CA), Canales; Eda (Foster City, CA), Cho; Aesop (Foster City, CA), Kim; Choung U. (Foster City, CA), Cottell; Jeromy J. (Foster City, CA), Desai; Manoj C. (Foster City, CA), Halcomb; Randall L. (Foster City, CA), Krygowski; Evan S. (Foster City, CA), Lazerwith; Scott E. (Foster City, CA), Liu; Qi (Foster City, CA), Mackman; Richard (Foster City, CA), Pyun; Hyung-Jun (Foster Cit, CA), Saugier; Joseph H. (Foster City, CA), Trenkle; James D. (Foster City, CA), Tse; Winston C. (Foster City, CA), Vivian; Randall W. (Foster City, CA), Schroeder; Scott D. (Foster City, CA), Watkins; William J. (Foster City, CA), Xu; Lianhong (Foster City, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:13/291,977
Patent Claims: 1. A method of inhibiting HCV in a human comprising administering a compound of formula: ##STR01307## wherein: V is alkyl; L is benzimidazolyl; M is a 5-membered heteroaryl ring; A.sup.15 is: ##STR01308## and P is selected from: ##STR01309## or a pharmaceutically acceptable salt, or prodrug thereof to the human.

2. The method of claim 1 wherein the compound is a compound of formula: ##STR01310## or a pharmaceutically acceptable salt or prodrug thereof .

3. The method of claim 1 wherein the compound is a compound of formula: ##STR01311## or a pharmaceutically acceptable salt or prodrug thereof.

4. The method compound of claim 1 wherein P is selected from: ##STR01312##

5. The method of claim 1 wherein P is ##STR01313##

6. The method of claim 1 wherein P is ##STR01314##

7. The method of claim 1 wherein the compound is a compound of formula: ##STR01315## or a pharmaceutically acceptable salt or prodrug thereof.

8. The method of claim 1 wherein the compound is a compound of formula: ##STR01316## or a pharmaceutically acceptable salt or prodrug thereof.

9. The method of claim 1 wherein the compound is a compound of formula: ##STR01317## wherein: V is alkyl; M is a 5-membered heteroaryl ring; and A.sup.15 is: ##STR01318## or a pharmaceutically acceptable salt or prodrug thereof.

10. The method of claim 1 wherein the compound is a compound of formula: ##STR01319## wherein: V is alkyl; and A.sup.15 is: ##STR01320## or a pharmaceutically acceptable salt or prodrug thereof.

11. The method of claim 1 wherein each V is: ##STR01321##

12. The method of claim 1 wherein the compound is a compound of formula: ##STR01322## or ##STR01323## or a pharmaceutically acceptable salt or prodrug thereof.

13. The method of claim 1 wherein the compound is a compound of formula: ##STR01324## or a pharmaceutically acceptable salt or prodrug thereof.

14. The method of claim 1, further comprising administering at least one additional therapeutic agent.

15. The method of claim 14, wherein said additional therapeutic agent is selected from the group consisting of ribavirin analogs, NS3 protease inhibitors, NS5b polymerase inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV.

16. The method of claim 14, wherein said additional therapeutic agent is a nucleoside analogue.

17. The method of claim 16, wherein said nucleoside analogue is selected from ribavirin, viramidine, levovirin, an L-nucleoside, and isatoribine.

18. The method of claim 13, further comprising administering at least one additional therapeutic agent.

19. The method of claim 18, wherein said additional therapeutic agent is selected from the group consisting of ribavirin analogs, NS3 protease inhibitors, NS5b polymerase inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV.

20. The method of claim 18, wherein said additional therapeutic agent is a nucleoside analogue.

21. The method of claim 20, wherein said nucleoside analogue is selected from ribavirin, viramidine, levovirin, an L-nucleoside, and isatoribine.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc